Abstract
Testicular germ cell tumours are the most common solid malignancies in young men. They are characterized by distinct biologic features and clinical behaviour, being curable even in a very advanced stage of metastatic disease.
Despite the high rate of cured and surviving patients, they still represent the leading cause of cancer-related mortality in this group of patients; a proportion of the survivors also suffer from late side-effects of the therapy leading to their increased morbidity and decreasing quality of life. The current management of patients with these tumours therefore aims at more individualized treatment approach, looking for novel prognostic factors and modes of specific targeted therapy.